Every Form 4 that Recursion Pharmaceuticals, Inc. (RXRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RXRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RXRX filings page.
Recursion Pharmaceuticals Chief Scientific Officer David Hallett reported equity compensation transactions in Class A common stock. On February 6, 2026, he acquired 502,064 shares at $0 per share from a restricted stock unit (RSU) grant that vests in sixteenth installments starting May 15, 2026 and every three months thereafter. He also acquired 24,254 shares at $0 per share from an RSU that vested immediately on the grant date. On the same day, 11,400 shares were withheld at $3.98 per share to cover tax obligations related to RSU settlement. After these transactions, Hallett directly owned 1,109,059 Class A shares.
Recursion Pharmaceuticals director Christopher Gibson reported several stock transactions in early February 2026. On February 4, he converted 40,000 shares of Class B Common Stock into Class A at $0 per share, then sold 40,000 Class A shares at $4.12 under a pre-arranged Rule 10b5-1 trading plan.
On February 6, Gibson received 30,346 Class A shares from restricted stock units that vested immediately at $0, and 10,364 shares were withheld at $3.56 to cover taxes. After these transactions, he directly held 933,821 Class A shares, alongside sizable option and convertible Class B positions.
Recursion Pharmaceuticals director Blake Borgeson sold 220,000 shares of Class A common stock on February 3, 2026 at $4.20 per share. The sale was made under a Rule 10b5-1 trading plan adopted on August 31, 2025. After this transaction, he beneficially owned 6,429,863 shares, held directly.
Recursion Pharmaceuticals director Christopher Gibson reported a planned share sale and related conversion. On January 20, 2026, he converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock at $0 per share pursuant to the Class B conversion feature. The same day, he sold 40,000 Class A shares at $4.47 per share under a Rule 10b5-1 trading plan adopted on May 12, 2025.
After these transactions, Gibson directly owned 913,839 shares of Class A Common Stock. He also reported additional indirect Class A holdings through entities he manages or serves as trustee, including 386,000 shares via LAHWRAN-3 LLC, 388,000 shares via LAHWRAN-4 LLC, and 50,000 shares via the Gibson Family Trust, as well as multiple outstanding stock options with various exercise prices and expirations.
Recursion Pharmaceuticals director Blake Borgeson reported selling 220,000 shares of the company’s Class A common stock on January 6, 2026 at a price of $4.36 per share. After this transaction, he beneficially owned 6,649,863 shares of Class A common stock in direct ownership.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that Borgeson adopted on August 31, 2025. Such plans are designed to allow insiders to sell shares according to a preset schedule or conditions, helping separate routine liquidity transactions from day-to-day market or company developments.
Recursion Pharmaceuticals director Christopher Gibson reported several share moves on January 5, 2026. He converted 60,000 shares of Class B Common Stock into 60,000 shares of Class A Common Stock at a stated price of $0, then sold 40,000 Class A shares at $4.25 per share and made a gift of 20,000 Class A shares. After these transactions, he directly held 913,839 shares of Class A Common Stock.
The filing also shows he directly holds 4,663,334 shares of Class B Common Stock, each convertible into one Class A share, and additional Class B holdings through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust. Multiple stock options to buy Class A shares remain outstanding with exercise prices ranging from $2.48 to $11.40 and expirations between 2030 and 2035. The conversion, sale, and gift were made under a Rule 10b5-1 trading plan adopted on May 12, 2025.
Recursion Pharmaceuticals director Dean Y. Li received a new equity grant. On 01/02/2026, he was awarded 2,381 shares of Class A Common Stock at a price of $0. The filing states these shares were issued under the company’s Outside Director Compensation Policy, meaning they represent routine board compensation rather than an open-market purchase. After this grant, Li directly beneficially owned 1,240,909 Class A shares, in addition to indirect holdings through the Dean Y. Li Revocable Trust, the Dean Y. Li GRAT, and the Dean Y. Li 2021 Family Trust.
Recursion Pharmaceuticals, Inc. reported an insider equity transaction by its Chief Financial Officer on 12/15/2025. The filing shows that 7,057 shares of Class A common stock were disposed of at $4.33 per share. According to the footnote, these shares were withheld by the company to cover tax withholding and remittance obligations related to the net settlement of restricted stock units, rather than an open-market sale.
After this tax withholding event, the reporting person beneficially owned 782,933 shares of Class A common stock directly. The transaction is characterized with code "F," which typically denotes payment of tax liability by withholding securities incident to vesting of equity awards.
Recursion Pharmaceuticals, Inc. (RXRX) Chief Financial Officer reported a routine share withholding related to equity compensation. On 11/25/2025, 2,271 shares of Class A common stock were disposed of in a transaction coded "F" at a price of $4.03 per share. This code indicates shares were withheld by the company to cover tax withholding and remittance obligations arising from the net settlement of restricted stock units.
Following this transaction, the reporting officer beneficially owns 789,990 shares of Class A common stock in direct ownership. No new derivative securities transactions were reported in this filing.
Recursion Pharmaceuticals, Inc. (RXRX) reported an insider transaction by its Chief Financial Officer on Form 4. On 11/17/2025, 11,908 shares of Class A common stock were withheld by the company at a price of $4.14 per share to cover tax obligations from the net settlement of restricted stock units. After this tax withholding, the CFO directly beneficially owns 792,261 shares of Class A common stock.
Recursion Pharmaceuticals, Inc. (RXRX) reported an insider equity transaction by a director and officer (Chief R&D Commercial Officer) on 11/17/2025. The filing shows that 17,584 shares of Class A common stock were disposed of at $4.14 per share under transaction code "F," which indicates shares were withheld by the company to cover tax obligations on the net settlement of restricted stock units.
After this tax withholding event, the reporting person directly beneficially owns 735,538 shares of Class A common stock. The transaction reflects administrative share withholding for taxes rather than an open-market sale.
Recursion Pharmaceuticals (RXRX) CEO/Director Form 4 shows routine equity activity. On 11/17/2025, 40,390 Class A shares were withheld at $4.14 to cover tax obligations from net-settled restricted stock units, leaving 913,839 Class A shares directly owned. On 11/19/2025, the insider converted 40,000 Class B shares into Class A at $0 and sold 40,000 Class A shares at $4.16 under a Rule 10b5-1 trading plan adopted on May 12, 2025, maintaining direct ownership at 913,839 Class A shares.
The insider also reports derivative holdings, including Class B shares convertible into Class A with no expiration date and multiple stock options with exercise prices ranging from $2.48 to $11.40 and expirations extending to 2035. Some Class B holdings are reported indirectly through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust.
Recursion Pharmaceuticals (RXRX) reported an insider equity award on 11/05/2025. A director and officer (Chief R&D Commercial Officer) received 84,925 Class A RSUs at $0 and a stock option for 169,851 shares at an exercise price of $4.96. The RSUs vest 1/16 on February 15, 2026 and every three months thereafter; the option vests 1/48 starting December 5, 2025 with monthly installments thereafter. Following the awards, direct ownership was 753,122 Class A shares.
Recursion Pharmaceuticals (RXRX) CEO and Director reported insider transactions on 11/04/2025 under a Rule 10b5-1 plan adopted May 12, 2025. The filing shows a conversion of 60,000 shares of Class B into Class A at $0 (Code C), a sale of 40,000 Class A shares at $5.21 (Code S), and a gift of 20,000 Class A shares (Code G). Following these transactions, the reporting person directly beneficially owned 954,229 Class A shares. The filing also lists ongoing stock option grants with multi-year vesting schedules.